X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADG126 (muzastotug) is a fully human anti-CTLA-4 SAFEbody. SAFEbody® is company's proprietary precision antibody masking platform designed to enable an antibody to bind its target specifically. It is under development for metastatic microsatellite-stable colorectal cancer.
Lead Product(s): AMP945,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
ADG126 (muzastotug) is a masked anti-CTLA-4 SAFEbody. It is currently being evaluated in phase 1/2 clinical trials for the treatment of microsatellite-stable colorectal cancer.
Lead Product(s): AMP945,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The collaboration aims for the development of novel masked antibody-drug conjugate (ADC) candidates, including ADG126 leveraging Adagene’s proprietary SAFEbody precision masking technology.
Lead Product(s): ADG126,Toripalimab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: $12.1 million
Deal Type: Collaboration May 04, 2023
Details:
TPST-1120 is an oral, small molecule, selective PPAR⍺ antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for hepatocellular carcinoma.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Tempest Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
ADG126 is a fully human anti-CTLA-4 SAFEbody designed to mask the antibody binding site of ADG126, which would be unmasked in the TME, where activated ADG126 would block CTLA-4 and deplete regulatory T-cells by means of ADCC.
Lead Product(s): ADG126,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
ADG126 is a fully human anti-CTLA-4 SAFEbody designed to mask the antibody binding site of ADG126, which would be unmasked in the TME, where activated ADG126 would block CTLA-4 and deplete regulatory T-cells by means of ADCC.
Lead Product(s): ADG126,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Under the collaboration, Roche will sponsor and conduct a randomized phase 1b/2 multi-national trial to evaluate the efficacy, safety and pharmacokinetics of ADG126 in combination with bevacizumab and atezolizumab, versus atezolizumab and bevacizumab alone.
Lead Product(s): ADG126,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 16, 2022
Details:
Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ADG116 across dosing levels, with repeat dosing both as monotherapy and in combination with anti-PD-1 therapy.
Lead Product(s): ADG116,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG116
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
ADG126 monotherapy showed an unprecedented clinical safety profile at dosing levels up to 20 mg/kg when administered to this heavily pretreated patient population once every three weeks.
Lead Product(s): ADG126,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
ADG126, SAFEbody applies precision-masking technology to the parental anti-CTLA-4 antibody, ADG116, for conditional activation in the TME to expand the therapeutic index and further address safety concerns with existing CTLA-4 therapies.
Lead Product(s): ADG126,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
